PLX195341

GSE126078: The phenotypic diversity of treatment-refractory metastatic castration-resistant prostate cancer

• Organsim human
• Type RNASEQ
• Target gene
• Project ARCHS4

The widespread and long-term use of potent therapies designed to repress androgen receptor (AR) signaling is changing the molecular and phenotypic landscapes of prostate cancer. We conducted molecular profiling of metastatic castration-resistant prostate cancer (mCRPC) patient specimens and patient-derived xenograft models and identified five distinct mCRPC phenotypes. Herein, we characterize an AR-low phenotype that has low AR expression with concomitant decreases in a subset of AR regulated genes, and an amphicrine phenotype that has both AR and neuroendocrine activity in the same cell. Furthermore, our data highlight an emerging squamous cell mCRPC phenotype. SOURCE: Ilsa Coleman (icoleman@fhcrc.org) - Peter Nelson Fred Hutchinson Cancer Research Center